



GlaxoSmithKline Pharmaceuticals Ltd.

GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

26th July 2021

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sirs,

Subject: Media release: Q1 of 2021-22

Please find enclosed a press release issued by the Company in respect of financial results for the quarter ended 30th June 2021.

This is for your information and record.

Yours faithfully
For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151



GlaxoSmithKline Pharmaceuticals Limited delivers 19% revenue growth for the quarter ended June 30, 2021

Decides to transfer *Iodex* and *Ostocalcium* brand rights to GSK Asia (consumer entity) for Rs 1649 crores

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended June 30, 2021. Revenue for the quarter came in at Rs 773 crores recording a growth of 19%. Profit Before Tax for the quarter at Rs.164 crores recorded a growth of 10%.

The company also announced its decision to transfer its rights in relation to the *Iodex* and *Ostocalcium* brands to GlaxoSmithKline Asia Private Limited, subject to shareholder approval, for an aggregate consideration of Rs 1649 crores.

Commenting on the results, **Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited**, said, "We continue to show remarkable resilience and deliver growth despite the headwinds caused by the COVID-19 pandemic. Our pharmaceutical manufacturing team worked round the clock to fulfill significantly increased demand for our key brands, especially for *Calpol* (paracetamol). This effort ensured that patients continued to have access to this important medication during the pandemic. While our vaccines business was impacted due to low vaccination rates, many of our key brands witnessed strong growth fuelled by disciplined execution, enhanced digital capabilities and agility in the market resulting in market share gains."

Commenting on the transfer of brand rights, Mr. Venkatesh added, "As part of our parent GSK plc's new ambition to create two world class companies in Pharmaceuticals and Consumer Healthcare, we have decided to transfer our rights in relation to the *Iodex* and *Ostocalcium* brands to GlaxoSmithKline Asia Private Limited. The transaction is expected to be completed before the end of the year, subject to shareholder approval and the customary closing conditions, including relevant regulatory approvals.

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com

Media Contact

Ransom D'Souza
Communications & Government Affairs
Email: ransom.a.dsouza@gsk.com
